Pecuniary valuation

The NeuroProtect team plans to strike a deal with Big Pharma when significant milestones are achieved. The most crucial milestones are:
  • IND received
  • Phase 1 done
  • Phase 2 done
We expect that after each of these milestones, the valuation of the company is going to increase significantly. The references are listed in Table 1 (see above). Table 1 contains only public information. It does not contain all information because most Big Pharma companies do not reveal such sensitive commercial information. Our estimation is that disclosed to the public information is only 35-40% of overall payments.


Estimated NeuroProtect Valuation: